IL317385A - Prevention or mitigation of adverse effects related to recombinant viral vectors - Google Patents
Prevention or mitigation of adverse effects related to recombinant viral vectorsInfo
- Publication number
- IL317385A IL317385A IL317385A IL31738524A IL317385A IL 317385 A IL317385 A IL 317385A IL 317385 A IL317385 A IL 317385A IL 31738524 A IL31738524 A IL 31738524A IL 317385 A IL317385 A IL 317385A
- Authority
- IL
- Israel
- Prior art keywords
- mitigation
- prevention
- adverse effects
- viral vectors
- recombinant viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22190354 | 2022-08-15 | ||
| PCT/EP2023/072361 WO2024038002A1 (en) | 2022-08-15 | 2023-08-14 | Prevention or mitigation of adverse effects related to recombinant viral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317385A true IL317385A (en) | 2025-02-01 |
Family
ID=83447887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317385A IL317385A (en) | 2022-08-15 | 2023-08-14 | Prevention or mitigation of adverse effects related to recombinant viral vectors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260000670A1 (en) |
| EP (1) | EP4572793A1 (en) |
| JP (1) | JP2025526697A (en) |
| KR (1) | KR20250050869A (en) |
| CN (1) | CN119730884A (en) |
| AU (1) | AU2023327682A1 (en) |
| CA (1) | CA3264415A1 (en) |
| IL (1) | IL317385A (en) |
| MX (1) | MX2025001461A (en) |
| TW (1) | TW202416993A (en) |
| WO (1) | WO2024038002A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| JP6342886B2 (en) | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Composition and method for highly efficient gene transfer using AAV capsid variants |
| NZ716102A (en) | 2013-07-22 | 2021-12-24 | The Children’S Hospital Of Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| US11021545B2 (en) * | 2018-07-31 | 2021-06-01 | The Regents Of The University Of California | Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents |
| US20230277633A1 (en) * | 2020-06-05 | 2023-09-07 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical composition of enzymes and viruses and application thereof |
-
2023
- 2023-08-14 EP EP23755396.1A patent/EP4572793A1/en active Pending
- 2023-08-14 KR KR1020257003333A patent/KR20250050869A/en active Pending
- 2023-08-14 WO PCT/EP2023/072361 patent/WO2024038002A1/en not_active Ceased
- 2023-08-14 TW TW112130421A patent/TW202416993A/en unknown
- 2023-08-14 AU AU2023327682A patent/AU2023327682A1/en active Pending
- 2023-08-14 CN CN202380058024.XA patent/CN119730884A/en active Pending
- 2023-08-14 CA CA3264415A patent/CA3264415A1/en active Pending
- 2023-08-14 JP JP2025507359A patent/JP2025526697A/en active Pending
- 2023-08-14 IL IL317385A patent/IL317385A/en unknown
-
2025
- 2025-02-05 MX MX2025001461A patent/MX2025001461A/en unknown
- 2025-02-12 US US19/052,088 patent/US20260000670A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260000670A1 (en) | 2026-01-01 |
| EP4572793A1 (en) | 2025-06-25 |
| MX2025001461A (en) | 2025-03-07 |
| TW202416993A (en) | 2024-05-01 |
| CN119730884A (en) | 2025-03-28 |
| JP2025526697A (en) | 2025-08-15 |
| KR20250050869A (en) | 2025-04-15 |
| AU2023327682A1 (en) | 2024-12-05 |
| CA3264415A1 (en) | 2024-02-22 |
| WO2024038002A1 (en) | 2024-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100202B (en) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins | |
| IL288419A (en) | Recombinant herpesvirales vector | |
| BR112022001912A2 (en) | Cellular compositions comprising viral vectors and treatment methods | |
| MA55480A (en) | METHODS OF MAKING RECOMBINANT VIRAL VECTORS | |
| IL314658A (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| IL321162A (en) | Adeno-associated viral vectors for proper packaging of repetitive elements | |
| CA3264415A1 (en) | Prevention or mitigation of adverse effects related to recombinant viral vectors | |
| IL316348A (en) | Prevention or mitigation of t-cell engaging agent-related adverse effects | |
| KR102248420B9 (en) | Recombinant vector containing the target sequence of miR-142-3p | |
| ZA202203832B (en) | Co-production of high purity isobutane and butene-1 from mixed c4s | |
| CA206918S (en) | Set of eye shields | |
| ZA202109060B (en) | Stabilization of suspension concentrates by hydrophobic fumed silica | |
| ZA202109011B (en) | Stable formulations of recombinant proteins | |
| HUE073273T2 (en) | Stabilization of suspension concentrates by ethoxylated ricinolein | |
| GB202312083D0 (en) | Viral vector | |
| EP4370698A4 (en) | Compositions for and methods of improving viral vectors | |
| EP4588194A4 (en) | Suppression of elemental yield outside the range at gamma beams | |
| GB202111753D0 (en) | Instruction interrupt suppression of overflow exception | |
| HK40088883A (en) | Compositions for preservation of viral vectors | |
| GB202211673D0 (en) | Viral vector | |
| GB202510959D0 (en) | Improved viral vectors | |
| GB202104320D0 (en) | Enhancement of viral titres | |
| EP4507699A4 (en) | Chemogenetic regulation of peptide function | |
| HK40103866A (en) | Use of cd8-targeted viral vectors | |
| CA222234S (en) | Pair of gloves |